Clinical trials: Urinary System Tumor
Bladder Cancer
Autophagy Bladder Cancer
Bladder cancer is the most common malignancy of the urinary tract. It represents the 7th most commonly diagnosed cancer in male population worldwide and drops to the 11th when both genders are considered .
- Trial name
- NCT03254888
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Assiut University
Carcinoma, Renal Cell
Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens
The aim of this study is to determine preliminary efficacy of capecitabine and interferon-alpha in second-line after interleukin-2 based regimens in patients with MRCC
- Trial name
- NCT00591188
- Testing
- capecitabine, interferon-alpha
- Where
- Russia
- Volunteers
- 49 people
- Sponsor
- Kidney Cancer Research Bureau
Clear Cell Renal Cell Carcinoma, VHL Syndrome
Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer
The goal of this study is to comprehensively map intra and inter tumor heterogeneity of ccRCC in VHL patients through the use of imaging, molecular biology and genomics techniques.
- Trial name
- ITHORinVHL (NCT06195150)
- Testing
- Blood collection
- Where
- Italy
- Volunteers
- 3 people
- Sponsor
- IRCCS San Raffaele
Bladder Cancer
Exploring Engagement Dynamics Among Individuals Impacted by Bladder Cancer
The study seeks to delve into the firsthand experiences of patients diagnosed with bladder cancer who partake in a separate clinical trial featuring a specific medical intervention.
- Trial name
- NCT06009510
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Hematuria, Nephrolithiasis
Diagnostic Relevance of Laser Confocal Microscopy for the Screening of Upper Urinary Tract Tumors
Upper Urinary Tract Tumors have an incidence of 1 to 2 cases for 100 000 persons per year. The standard treatment for these tumors is the ablation of the kidney, ureter and a part of the bladder surrounding the ureteral orifice.
- Conditions
- Hematuria, Nephrolithiasis, Cancer of Urinary Tract, Ureteropelvic Junction Obstruction
- Trial name
- UROVISIO (NCT02276924)
- Testing
- Laser confocal microscopy
- Where
- France
- Volunteers
- 29 people
- Sponsor
- Lille Catholic University
Bladder Cancer
The iBlad App - a National, Exploratory Study on a Multimodality Smartphone App for Bladder Cancer Patients
The aims of this project are: to develop and implement a national multimodality application for patients with bladder cancer that builds upon knowledge from the iBLAD study.
- Trial name
- iBLAD-app (NCT05710159)
- Testing
- iBLAD Application to monitor symptoms and quality of life by the use of pateint-reported outcomes
- Where
- 2 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Odense University Hospital
Cancer, Childhood Cancer
Bladder and Bone Effects of Pelvic Radiation Therapy in Childhood Cancer Survivors
The aim of this study is to measure and evaluate the effects of pelvic external beam radiation therapy (EBRT) on lower urinary tract (LUT) function and bone mineralization.
- Trial name
- NCT05818462
- Testing
- Uroflow testing, Bladder Scan, Dysfunctional Voiding Scoring System Survey
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Colorado, Denver
Renal Cancer
Mechanisms of Anti-VEGF Induced Hypertension
Background: High blood pressure is a common complication observed in cancer patients prescribed anti-VEGF drugs. Increased blood pressure increases the risk of heart attacks and strokes, thus adversely affecting survival and…
- Trial name
- NCT02156310
- Where
- Australia
- Volunteers
- 2,000 people
- Sponsor
- Arduino Mangoni
Endoscopic Bladder Cancer Diagnosis With Raman
In Vivo Proof-of-principle Study of Raman Spectroscopy in Trial Participants With Bladder Tumours
The purpose with this clinical investigation is to perform Raman spectroscopy inside the vivid bladder and to acquire Raman spectra of normal and tumour bladder tissue, and in a post-processing step to determine the grade of the…
- Trial name
- NCT05124106
- Testing
- Raman Spectrometry
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
Carcinoma of Urinary Tract, Urethral Carcinoma
Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
This multicenter trial will enroll participants with metastatic transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis who have had disease progression on first-line platinum-based chemotherapy regimens.
- Conditions
- Carcinoma of Urinary Tract, Urethral Carcinoma, Carcinoma of Ureter, Carcinoma of Renal Pelvis
- Trial name
- NCT01282463
- Testing
- Docetaxel, Ramucirumab DP, Icrucumab
- Where
- 32 sites in United States, Canada
- Volunteers
- 148 people
- Sponsor
- Eli Lilly and Company
Neuroblastoma, Central Nervous System Tumors
Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas
Studies have provided evidence that residual microscopic malignant cells in autologous bone marrow or blood stem cell grafts can contribute to posttransplant relapse.
- Conditions
- Neuroblastoma, Central Nervous System Tumors, Lymphomas, Wilms Tumor
- Trial name
- NCT00152126
- Testing
- Stem Cell Transplantation, Busulfan, Melphalan
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- St. Jude Children's Research Hospital
Bladder Cancer, Breast Cancer
LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors
RATIONALE: The LMB-9 immunotoxin may be able to locate tumor cells and kill them without harming normal cells. This may be an effective treatment for advanced solid tumors.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00019435
- Testing
- LMB-9 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Non Small Cell Lung Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, High Grade Serous Adenocarcinoma of Ovary
- Trial name
- PRESERVE-009 (NCT05858736)
- Testing
- AI-061
- Where
- 5 sites in Australia
- Volunteers
- 18 people
- Sponsor
- OncoC4, Inc.
Metastatic Kidney Cancer, Metastatic Renal Cell Carcinoma
Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer
One third of patients with kidney cancer are diagnosed in the metastatic stage, and among patients with a localized form, about 30 to 40% will develop metastases after surgery.
- Trial name
- CA9CRM (NCT00942058)
- Testing
- Serum and urinary CA9 level
- Where
- 3 sites in France
- Volunteers
- 16 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Bladder Cancer
Detection of K14 in Bladder Cancer With a Non Invasive Technique
By an invasive technique keratin 14 has been identified as a prognostic factor in bladder cancer. This study aims to analyze whether through a non-invasive technique keratin 14 can be used as a diagnostic and prognostic marker…
- Trial name
- NCT02027649
- Where
- Spain
- Volunteers
- 400 people
- Sponsor
- Corporacion Parc Tauli
Transitional Cell Carcinoma of Urinary Bladder
Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.
The purpose of this study is to define the optimal management of localised transitional cell carcinoma (TCC) of the urinary bladder. The main objective is to evaluate whether chemoradiation is superior to radiotherapy alone.
- Trial name
- NCT00330499
- Testing
- Cisplatin, External beam radiation treatment
- Where
- 22 sites in Australia, New Zealand
- Volunteers
- 67 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Metastatic Cancer, Solid Tumors
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.
- Conditions
- Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer
- Trial name
- NCT02903914
- Testing
- INCB001158, Pembrolizumab
- Where
- 20 sites in United States, Italy and 2 more
- Volunteers
- 260 people
- Sponsor
- Incyte Corporation
Metastatic Renal Cancer
Lu-177 PSMA Treatment in Cell Renal Carcinoma
Summary Renal Cell Carcinoma (RCC) consists of 2% of all malignencies. RCCs are generally divided to histopathological subtypes as clear cell and non-clear cell variants. Clear cell variant responsible for the 75-80% of all RCCs.
- Trial name
- NCT06959433
- Testing
- Lu-177 PSMA-617
- Volunteers
- 20 people
- Sponsor
- Ankara University
Metastatic Renal Cell Cancer, GIST
Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib
Patients with advanced kidney cancer or GIST (Gastro Intestinal Stromal Tumor: this is a tumor of the intestines) may be eligible for treatment with one of the following drugs: sunitinib (Sutent ®) or sorafenib (Nexavar ®).
- Trial name
- NCT01246843
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Radboud University Medical Center
Bladder Cancer, CIS
A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)
The purpose of this study is to observe and describe the effectiveness and local tolerability of intravesical treatment with valrubicin for non-muscle invasive bladder cancer (NMIBC) in a cohort of subjects treated under routine…
- Trial name
- NCT01314664
- Where
- 11 sites in United States
- Volunteers
- 15 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.